Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002361002 | SCV002665827 | uncertain significance | Cardiovascular phenotype | 2019-09-26 | criteria provided, single submitter | clinical testing | The p.E23840K variant (also known as c.71518G>A), located in coding exon 180 of the TTN gene, results from a G to A substitution at nucleotide position 71518. The glutamic acid at codon 23840 is replaced by lysine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Clinical Genetics, |
RCV001699884 | SCV001921683 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV001699884 | SCV001928540 | uncertain significance | not provided | no assertion criteria provided | clinical testing |